(Q39186027)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

0 references

1 reference

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Murat Yalcin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Hung-Yun Lin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Thangirala Sudha

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Dhruba J Bharali

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Ran Meng

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Heng-Yuan Tang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Faith B Davis

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Steven C Stain

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Paul J Davis

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

28 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

176-185

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23456390%20AND%20SRC:MED&resulttype=core&format=json

Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Adjuvant therapy in pancreatic cancer: a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Advanced pancreatic carcinoma: current treatment and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Novel agents for the treatment of adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, alphavbeta3-integrin, and TGF-beta1 in response to ANG II and high glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Integrins in cancer: biological implications and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Involvement of alpha(v)beta3 integrins in osteoclast function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Human platelet aggregation and degranulation is induced in vitro by L-thyroxine, but not by 3,5,3'-triiodo-L-thyronine or diiodothyropropionic acid (DITPA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Thyroid hormone and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Metabolic effects of thyroid hormone derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Integrin alphaVbeta3 contains a receptor site for resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

The role of the EGFR signaling in tumor microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Disparate effects of thyroid hormone on actions of epidermal growth factor and transforming growth factor-alpha are mediated by 3',5'-cyclic adenosine 5'-monophosphate-dependent protein kinase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Thyroid hormone promotes the phosphorylation of STAT3 and potentiates the action of epidermal growth factor in cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Oscillatory flow-induced proliferation of osteoblast-like cells is mediated by alphavbeta3 and beta1 integrins through synergistic interactions of focal adhesion kinase and Shc with phosphatidylinositol 3-kinase and the Akt/mTOR/p70S6K pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Integrin alphavbeta3 upregulates integrin-linked kinase expression in human ovarian cancer cells via enhancement of ILK gene transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Conceptual framework for cutting the pancreatic cancer fuel supply

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Activation of the MEK/MAPK pathway is involved in bryostatin1-induced monocytic differenciation and up-regulation of X-linked inhibitor of apoptosis protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Molecular aspects of thyroid hormone actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Membrane receptor for thyroid hormone: physiologic and pharmacologic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Preparation and biological evaluation of multifunctional PLGA-nanoparticles designed for photoacoustic imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

EGFR and KRAS Mutational Analysis and Their Correlation to Survival in Pancreatic and Periampullary Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12672-013-0137-Y

Challenges in developing targeted therapy for pancreatic adenocarcinoma

21 January 2018

1 reference

12 December 2020

[Expression of angiogenic factors in pancreatic carcinoma cell and their significance]

1 reference

12 December 2020

Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK- and p53-dependent mechanism

1 reference

12 December 2020

Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.

1 reference

12 December 2020

Nanoparticles based on PLGA:poloxamer blends for the delivery of proangiogenic growth factors

1 reference

12 December 2020

Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac).

1 reference

12 December 2020

Identification of genes regulated by an interaction between alphavbeta3 integrin and vitronectin in murine decidua

1 reference

12 December 2020